Skip to menu Skip to content Skip to footer
Associate Professor Timothy Wells
Associate Professor

Timothy Wells

Email: 

Overview

Background

Dr Timothy Wells joined the Frazer Institute in 2016 as a Senior Research Fellow. His research aims to find novel methods of treating multi-drug resistant bacteria, by examing the interactions between the host immune system and Gram negative bacteria. His research largely focuses on Pseudomonas aeruginosa acute and chronic infections, espeically in people living with cystic fibrosis. Dr Wells is passionate about making his research as clinically relevant as possible, with his work previously having led to novel treatment of critically ill patients. His research uses a mixture of molecular microbiology, immunology and genomic approaches.

Availability

Associate Professor Timothy Wells is:
Available for supervision
Media expert

Qualifications

  • Bachelor (Honours) of Biotechnology, The University of Queensland
  • Doctor of Philosophy, The University of Queensland

Research interests

  • Pseudomonas aeruginosa

    The T-Wells lab is interested in all infections by Pseudomonas aeruginosa whether that be chronic lung infection, wound and joint infections, acute pneumonia, UTIs and bacteremia.

  • Bacterial chronic lung infections

    The T-Wells lab is interested in bacterial infections in people with cystic fibrosis, bronchiectasis, COPD and post-lung transplant

Research impacts

Dr Wells’s original work in the field of host- pathogen interactions during chronic lung infection has led to several key insights and direct translation to the clinic.

Antibody dependent enhancement of bacterial infection: Antibodies usually protect against bacterial infection, however Dr Wells' work has identified ‘cloaking antibodies’ in patients who have Pseudomonas aeruginosa infections. Cloaking antibodies paradoxically prevent immune killing of patient's bacterial strains. Importantly, high titres of cloaking antibodies has been associated with worse lung function and patient outcomes in people with cystic fibrosis, bronchiectasis and post-lung transplant. These antibodies are also prevelant in actue Pseduomonas infections such as bacteremia.

Novel treatment of multi-drug resistant Pseudomonas aeruginosa lung infection: As cloaking antibodies (cAbs) protect bacteria from immune killing, we hypothesised that cAb removal would restore normal immune killing. Three patients with chronic P. aeruginosa infections and cAb, who had exhausted all standard treatment options have now been treated via plasmapheresis. This treatment removes all antibody, including cAbs from the patients. After treatment, P. aeruginosa was undetectable in all patients, inflammatory markers were normal and lung function increased. As these patients had strains displaying resistance to many antibiotics used clinically, this is a novel treatment method for multi-drug resistant infections.

Works

Search Professor Timothy Wells’s works on UQ eSpace

80 works between 2004 and 2025

21 - 40 of 80 works

2023

Conference Publication

Goblet cell specific anti-apoptotic role of interleukin-24 in spondyloarthritis-associated ileitis

Cameron, A., Giri, R., Begun, J., Wells, T., Bergot, A. S. and Thomas, R. (2023). Goblet cell specific anti-apoptotic role of interleukin-24 in spondyloarthritis-associated ileitis. EULAR 2023 European Congress of Rheumatology, Milan, Italy, 31 May-3 June 2023. London, United Kingdom: BMJ Group. doi: 10.1136/annrheumdis-2023-eular.1346

Goblet cell specific anti-apoptotic role of interleukin-24 in spondyloarthritis-associated ileitis

2023

Conference Publication

TIGIT limits anti-bacterial immunity and is a potential target for immunotherapy

Souza-Fonseca-Guimaraes, Fernando, Rossi, Gustavo Rodrigues, Wells, Timothy and McCulloch, Timothy Ryan (2023). TIGIT limits anti-bacterial immunity and is a potential target for immunotherapy. IMMUNOLOGY2023™ Meeting, Washington, DC, United States, 11 - 15 May 2023. Rockville, MD, United States: The American Association of Immunologists. doi: 10.4049/jimmunol.210.supp.64.14

TIGIT limits anti-bacterial immunity and is a potential target for immunotherapy

2023

Journal Article

Effects of a postbiotic, with and without a saponin-based product, on turkey performance

Chaney, Evan, Miller, Elizabeth A., Firman, Jeffrey, Binnebose, Andrea, Kuttappan, Vivek and Johnson, Timothy J. (2023). Effects of a postbiotic, with and without a saponin-based product, on turkey performance. Poultry Science, 102 (5) 102607, 1-5. doi: 10.1016/j.psj.2023.102607

Effects of a postbiotic, with and without a saponin-based product, on turkey performance

2023

Conference Publication

Differential regulation of natural killer cells by tumor necrosis factor receptors 1 and 2

McCulloch, Timothy R., Rossi, Gustavo Rodrigues, Lam, Allie, Wong, Joshua, Kane, Lawrence P., Herold, Marco, Wells, Timothy and Souza-Fonseca-Guimaraes, Fernando (2023). Differential regulation of natural killer cells by tumor necrosis factor receptors 1 and 2. Immunology 2023™ Meeting, Washington, DC United States, 11-15 May 2023. Rockville, MD United States: American Association of Immunologists. doi: 10.4049/jimmunol.210.supp.72.28

Differential regulation of natural killer cells by tumor necrosis factor receptors 1 and 2

2023

Journal Article

IFI27 transcription is an early predictor for COVID-19 outcomes, a multi-cohort observational study

Shojaei, Maryam, Shamshirian, Amir, Monkman, James, Grice, Laura, Tran, Minh, Tan, Chin Wee, Teo, Siok Min, Rodrigues Rossi, Gustavo, McCulloch, Timothy R., Nalos, Marek, Raei, Maedeh, Razavi, Alireza, Ghasemian, Roya, Gheibi, Mobina, Roozbeh, Fatemeh, Sly, Peter D., Spann, Kirsten M., Chew, Keng Yih, Zhu, Yanshan, Xia, Yao, Wells, Timothy J., Senegaglia, Alexandra Cristina, Kuniyoshi, Carmen Lúcia, Franck, Claudio Luciano, dos Santos, Anna Flavia Ribeiro, Noronha, Lucia de, Motamen, Sepideh, Valadan, Reza, Amjadi, Omolbanin ... Tang, Benjamin (2023). IFI27 transcription is an early predictor for COVID-19 outcomes, a multi-cohort observational study. Frontiers in Immunology, 13 1060438, 1-14. doi: 10.3389/fimmu.2022.1060438

IFI27 transcription is an early predictor for COVID-19 outcomes, a multi-cohort observational study

2022

Conference Publication

Reduction of Salmonella Reading Using a Dairy-Originated Probiotic Bacterium, Propionibacterium Freudenreichii in Combination with a Live Attenuated Salmonella Typhimurium Vaccine in Growing Turkeys

Peichel, Claire, Manjankattil, Shijinarah, Dewi, Grace, Akhtar, Luna, Bina, Peter, Creek, Medora, Deniz, Kerem, Hobbs, John, Wichmann, Elaina, Feist, Emma, Schlosser, Mikayla, Johnson, Timothy J. J., Noll, Sally and Johny, Anup Kollanoor (2022). Reduction of Salmonella Reading Using a Dairy-Originated Probiotic Bacterium, Propionibacterium Freudenreichii in Combination with a Live Attenuated Salmonella Typhimurium Vaccine in Growing Turkeys. CARY: OXFORD UNIV PRESS INC. doi: 10.1093/jas/skac247.463

Reduction of Salmonella Reading Using a Dairy-Originated Probiotic Bacterium, Propionibacterium Freudenreichii in Combination with a Live Attenuated Salmonella Typhimurium Vaccine in Growing Turkeys

2022

Journal Article

Estimating biofuel contaminant concentration from 4D ERT with mixing models

Glaser, D. R., Henderson, R. D., Werkema, D. D., Johnson, T. J. and Versteeg, R. J. (2022). Estimating biofuel contaminant concentration from 4D ERT with mixing models. Journal of Contaminant Hydrology, 248 104027. doi: 10.1016/j.jconhyd.2022.104027

Estimating biofuel contaminant concentration from 4D ERT with mixing models

2022

Journal Article

CIS and TGF ‐β regulatory pathways influence immunity to bacterial infection

McCulloch, Timothy R., Rossi, Gustavo R., Schreuder, Jaring, Belz, Gabrielle T., Wells, Timothy J. and Souza‐Fonseca‐Guimaraes, Fernando (2022). CIS and TGF ‐β regulatory pathways influence immunity to bacterial infection. Immunology, 167 (1), 54-63. doi: 10.1111/imm.13516

CIS and TGF ‐β regulatory pathways influence immunity to bacterial infection

2022

Journal Article

Editorial: The Interplay of Host-Microbiome-Pathogen on Infectious Diseases

Maurer, John J., Simoes-Barbosa, Augusto, Johnson, Timothy J. and Conway, Tyrrell (2022). Editorial: The Interplay of Host-Microbiome-Pathogen on Infectious Diseases. Frontiers in Microbiology, 13 924807. doi: 10.3389/fmicb.2022.924807

Editorial: The Interplay of Host-Microbiome-Pathogen on Infectious Diseases

2022

Journal Article

Genomic diversity and antimicrobial resistance of Prevotella species isolated from chronic lung disease airways

Webb, Kasey A., Olagoke, Olusola, Baird, Timothy, Neill, Jane, Pham, Amy, Wells, Timothy J., Ramsay, Kay A., Bell, Scott C., Sarovich, Derek S. and Price, Erin P. (2022). Genomic diversity and antimicrobial resistance of Prevotella species isolated from chronic lung disease airways. Microbial Genomics, 8 (2) 000754. doi: 10.1099/mgen.0.000754

Genomic diversity and antimicrobial resistance of Prevotella species isolated from chronic lung disease airways

2022

Journal Article

Inhibition of the master regulator of Listeria monocytogenes virulence enables bacterial clearance from spacious replication vacuoles in infected macrophages

Tran, Thao Thanh, Mathmann, Carmen D., Gatica-Andrades, Marcela, Rollo, Rachel F., Oelker, Melanie, Ljungberg, Johanna K., Nguyen, Tam T. K., Zamoshnikova, Alina, Kummari, Lalith K., Wyer, Orry J. K., Irvine, Katharine M., Melo-Bolívar, Javier, Gross, Annette, Brown, Darren, Mak, Jeffrey Y. W., Fairlie, David P., Hansford, Karl A., Cooper, Matthew A., Giri, Rabina, Schreiber, Veronika, Joseph, Shannon R., Simpson, Fiona, Barnett, Timothy C., Johansson, Jörgen, Dankers, Wendy, Harris, James, Wells, Timothy J., Kapetanovic, Ronan, Sweet, Matthew J. ... Blumenthal, Antje (2022). Inhibition of the master regulator of Listeria monocytogenes virulence enables bacterial clearance from spacious replication vacuoles in infected macrophages. PLoS Pathogens, 18 (1) e1010166, e1010166. doi: 10.1371/journal.ppat.1010166

Inhibition of the master regulator of Listeria monocytogenes virulence enables bacterial clearance from spacious replication vacuoles in infected macrophages

2022

Journal Article

Effect of plant-derived antimicrobials against multidrug-resistant Salmonella Heidelberg in ground Turkey

Dewi, Grace, Manjankattil, Shijinaraj, Peichel, Claire, Jia, Shiliang, Nair, Divek, Vickers, Zata, Johnson, Timothy J., Cardona, Carol, Noll, Sally and Johny, Anup Kollanoor (2022). Effect of plant-derived antimicrobials against multidrug-resistant Salmonella Heidelberg in ground Turkey. Poultry Science, 101 (3) 101581, 101581. doi: 10.1016/j.psj.2021.101581

Effect of plant-derived antimicrobials against multidrug-resistant Salmonella Heidelberg in ground Turkey

2021

Other Outputs

Salmonella Typhimurium infection drives NK cell loss and conversion to ILC1-like cells, and CIS inhibition enhances antibacterial immunity

McCulloch, Timothy R., Rossi, Gustavo R., Wells, Timothy J. and Souza-Fonseca-Guimaraes, Fernando (2021). Salmonella Typhimurium infection drives NK cell loss and conversion to ILC1-like cells, and CIS inhibition enhances antibacterial immunity. doi: 10.1101/2021.11.29.470332

Salmonella Typhimurium infection drives NK cell loss and conversion to ILC1-like cells, and CIS inhibition enhances antibacterial immunity

2021

Other Outputs

IFI27 transcription is an early predictor for COVID-19 outcomes; a multi-cohort observational study

Shojaei, Maryam, Shamshirian, Amir, Monkman, James, Grice, Laura, Tran, Minh, Tan, Chin Wee, Rossi, Gustavo Rodrigues, McCulloch, Timothy R., Nalos, Marek, Chew, Keng Yih, Zhu, Yanshan, Xia, Yao, Wells, Timothy J., Senegaglia, Alexandra Cristina, Rebelatto, Carmen Lúcia Kuniyoshi, Franck, Claudio Luciano, dos Santos, Anna Flavia Ribeiro, de Noronha, Lucia, Motamen, Sepideh, Valadan, Reza, Amjadi, Omolbanin, Gogna, Rajan, Madan, Esha, Alizadeh-Navaei, Reza, Lamperti, Liliana, Zuñiga, Felipe, Nova-Lamperti, Estefania, Labarca, Gonzalo, Knippenberg, Ben ... Tang, Benjamin (2021). IFI27 transcription is an early predictor for COVID-19 outcomes; a multi-cohort observational study. doi: 10.1101/2021.10.29.21265555

IFI27 transcription is an early predictor for COVID-19 outcomes; a multi-cohort observational study

2021

Journal Article

Inferior outcomes in lung transplant recipients with serum Pseudomonas aeruginosa specific cloaking antibodies

Divithotawela, Chandima, Pham, Amy, Bell, Peter T., Ledger, Emma L., Tan, Maxine, Yerkovich, Stephanie, Grant, Michelle, Hopkins, Peter M., Wells, Timothy J. and Chambers, Daniel C. (2021). Inferior outcomes in lung transplant recipients with serum Pseudomonas aeruginosa specific cloaking antibodies. The Journal of Heart and Lung Transplantation, 40 (9), 951-959. doi: 10.1016/j.healun.2021.05.016

Inferior outcomes in lung transplant recipients with serum Pseudomonas aeruginosa specific cloaking antibodies

2021

Other Outputs

Genomic diversity and antimicrobial resistance of Prevotella spp. isolated from chronic lung disease airways

Webb, Kasey A., Olagoke, Olusola, Baird, Timothy, Neill, Jane, Pham, Amy, Wells, Timothy J., Ramsay, Kay A., Bell, Scott C., Sarovich, Derek S. and Price, Erin P. (2021). Genomic diversity and antimicrobial resistance of Prevotella spp. isolated from chronic lung disease airways. doi: 10.1101/2021.08.30.21262864

Genomic diversity and antimicrobial resistance of Prevotella spp. isolated from chronic lung disease airways

2021

Journal Article

Anti-LPS IgA and IgG can inhibit serum killing of Pseudomonas aeruginosa in patients with cystic fibrosis

Pham, Amy, Ledger, Emma L., Coggon, Carrie F., Henderson, Ian R., Reid, David W., Bell, Scott C., Smith, Daniel J. and Wells, Timothy J. (2021). Anti-LPS IgA and IgG can inhibit serum killing of Pseudomonas aeruginosa in patients with cystic fibrosis. Infection and Immunity, 89 (12) e00412-21, e0041221. doi: 10.1128/iai.00412-21

Anti-LPS IgA and IgG can inhibit serum killing of Pseudomonas aeruginosa in patients with cystic fibrosis

2021

Journal Article

Towards efficient immunotherapy for bacterial infection

McCulloch, Timothy R., Wells, Timothy J. and Souza-Fonseca-Guimaraes, Fernando (2021). Towards efficient immunotherapy for bacterial infection. Trends in Microbiology, 30 (2), 158-169. doi: 10.1016/j.tim.2021.05.005

Towards efficient immunotherapy for bacterial infection

2021

Journal Article

Mediation of interleukin-23 and tumor necrosis factor–driven reactive arthritis by Chlamydia-infected macrophages in SKG mice

Romand, Xavier, Liu, Xiao, Rahman, M. Arifur, Bhuyan, Zaied Ahmed, Douillard, Claire, Arora Kedia, Reena, Stone, Nathan, Roest, Dominique, Chew, Zi Huai, Cameron, Amy J., Rehaume, Linda M., Bozon, Aurélie, Habib, Mohammed, Armitage, Charles W., Nguyen, Minh Vu Chuong, Favier, Bertrand, Beagley, Kenneth, Maurin, Max, Gaudin, Philippe, Thomas, Ranjeny, Wells, Timothy J. and Baillet, Athan (2021). Mediation of interleukin-23 and tumor necrosis factor–driven reactive arthritis by Chlamydia-infected macrophages in SKG mice. Arthritis and Rheumatology, 73 (7) art.41653, 1200-1210. doi: 10.1002/art.41653

Mediation of interleukin-23 and tumor necrosis factor–driven reactive arthritis by Chlamydia-infected macrophages in SKG mice

2021

Journal Article

BamA and BamD are essential for the secretion of trimeric autotransporter adhesins

Rooke, Jessica L., Icke, Christopher, Wells, Timothy J, Rossiter, Amanda E., Browning, Douglas F., Morris, Faye C., Leo, Jack C., Schütz, Monika S., Autenrieth, Ingo B., Cunningham, Adam F., Linke, Dirk and Henderson, Ian R. (2021). BamA and BamD are essential for the secretion of trimeric autotransporter adhesins. Frontiers in Microbiology, 12 628879, 1-10. doi: 10.3389/fmicb.2021.628879

BamA and BamD are essential for the secretion of trimeric autotransporter adhesins

Funding

Current funding

  • 2024 - 2025
    Counteracting cloaking antibodies to treat intractable Pseudomonas infection.
    Cystic Fibrosis Foundation USA
    Open grant
  • 2024 - 2025
    Evaluation of plasmapheresis to treat intractable lung infections in people with cystic fibrosis
    Cystic Fibrosis Research Limited
    Open grant
  • 2023 - 2025
    Personalising diagnosis and treatment of Pseudomonas aeruginosa infection (NHMRC Ideas Grant administered by Griffith University)
    Griffith University
    Open grant

Past funding

  • 2023 - 2024
    Understanding and counteracting antibody-mediated inflammation driving lung damage
    Conquer Cystic Fibrosis Lung Health Transplant Grant
    Open grant
  • 2022 - 2024
    Antibody mediated exacerbation of Pseudomonas aeruginosa infected chronic wounds (an MSH-RSS administered by MSHHS)
    Metro South Research Support Scheme Co-funded Collaboration Grant
    Open grant
  • 2021 - 2024
    Impact and treatment of cloaking antibodies in Cystic Fibrosis
    Cystic Fibrosis Foundation USA
    Open grant
  • 2019 - 2021
    Paradoxical antibody: the role of antibody in exacerbating Pseudomonas lung infection
    NHMRC Project Grant
    Open grant
  • 2017
    Determining the scope and mechanism of inhibitory antibodies in bacterial lung infections.
    UQ Early Career Researcher
    Open grant

Supervision

Availability

Associate Professor Timothy Wells is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Available projects

  • Synergistic drugs to counteract cloaking antibodies

    Some patients infected with P. aeruginosa produce antibodies that, instead of fighting infection, actively protect P. aeruginosa from killing by the immune system. These ‘cloaking antibodies’ (cAb) target a lipopolysaccharide on the bacterial surface, known as O-antigen and form a physical barrier that stops the membrane attack complex (MAC) from reaching the bacterial outer membrane. Importantly, patients with cAb had greater disease severity and worse outcomes than patients with no cAb. Previous treatment for cAbs has focused on removal of the antibody, however a second attractive target is the infecting bacteria itself. We have recently investigated the bacterial requirements for the cloaking phenotype by creating strains with variable amounts and lengths of O-antigen expression. Serum bactericidal assays revealed that the serum-inhibition phenotype requires long and dense O-antigen We hypothesise that existing bacterial outer membrane modifying drugs can overcome the effect of cAbs, without cAb removal. This project will investigate potential synergistic drugs that could counteract cAbs, leading to bacterial killing.

Supervision history

Current supervision

  • Doctor Philosophy

    Targeting the outer membrane of Pseudomonas aeruginosa to disrupt the action of cloaking antibodies in cystic fibrosis

    Principal Advisor

  • Doctor Philosophy

    Investigating the gram-negative bacterial and host factors that drive sepsis outcomes

    Principal Advisor

    Other advisors: Dr Kate McCarthy

  • Doctor Philosophy

    Investigating B cell responses to Pseudomonas O-Antigen

    Principal Advisor

    Other advisors: Professor Ian Henderson

  • Master Philosophy

    Antibody-mediated exacerbation of Pseudomonas aeruginosa infected chronic wounds

    Principal Advisor

    Other advisors: Professor Kiarash Khosrotehrani

  • Doctor Philosophy

    The role of Two Partner Secretion proteins in the virulence of Pseudomonas aeruginosa

    Principal Advisor

    Other advisors: Professor Ian Henderson, Dr Jessica Rooke

  • Doctor Philosophy

    Investigating Pseudomonas aeruginosa persistance in the cystic fibrosis lung

    Principal Advisor

  • Doctor Philosophy

    The Role of PlpD in the Virulence of P. aeruginosa

    Principal Advisor

    Other advisors: Professor Ian Henderson, Dr Jessica Rooke

  • Master Philosophy

    Antibody mediated exacerbation of Pseudomonas aeruginosa infected chronic wounds

    Principal Advisor

    Other advisors: Professor Kiarash Khosrotehrani

  • Doctor Philosophy

    Improving Plasmapheresis: Investigating specific removal of cloaking antibodies to treat Pseudomonas aeruginosa

    Principal Advisor

    Other advisors: Professor Ian Henderson

  • Doctor Philosophy

    The impact of helpful and harmful immune responses on infection in the cystic fibrosis lung

    Principal Advisor

  • Doctor Philosophy

    Investigating Pseudomonas aeruginosa persistance in the cystic fibrosis lung

    Principal Advisor

  • Doctor Philosophy

    The role of cloaking antibodies in the pathophysiology, diagnosis, and treatment of inflammatory diseases

    Principal Advisor

    Other advisors: Professor Mark Morrison

  • Doctor Philosophy

    Investigating Pseudomonas aeruginosa persistence in the cystic fibrosis lung

    Principal Advisor

  • Doctor Philosophy

    The role of endoplasmic reticulum stress in spondyloarthropathy

    Associate Advisor

    Other advisors: Professor Ranjeny Thomas, Dr Anne-Sophie Bergot

  • Doctor Philosophy

    The Role of Endoplasmic Reticulum Stress in Autoimmune Inflammatory Arthritis

    Associate Advisor

    Other advisors: Professor Ranjeny Thomas, Dr Anne-Sophie Bergot

  • Doctor Philosophy

    High Mobility Group Box Family Member TOX2 in Innate Lymphoid Cell Development and Maintenance

    Associate Advisor

    Other advisors: Professor Gabrielle Belz

  • Doctor Philosophy

    Characterisation of the anti-mycobacterial activity of wollamide cyclic hexapeptides against Mycobacterium tuberculosis

    Associate Advisor

    Other advisors: Professor Antje Blumenthal

  • Doctor Philosophy

    Deciphering the protective program of innate and adaptive cells in pathogen infection

    Associate Advisor

    Other advisors: Professor Gabrielle Belz

  • Doctor Philosophy

    The Role of Endoplasmic Reticulum Stress in Autoimmune Inflammatory Arthritis

    Associate Advisor

    Other advisors: Professor Ranjeny Thomas, Dr Anne-Sophie Bergot

Completed supervision

Media

Enquiries

Contact Associate Professor Timothy Wells directly for media enquiries about:

  • cystic fibrosis infections
  • Pseudomonas aeruginosa

Need help?

For help with finding experts, story ideas and media enquiries, contact our Media team:

communications@uq.edu.au